Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
29 Results for "
psoriatic arthritis
" in MedChemExpress (MCE) Product Catalog:
Products (29)
29 Results for "psoriatic arthritis" in MCE Product Catalog:
36
36 Publications Verification
Synonyms: BMS-986165
24
24 Cited Publications
Research Areas:
SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
13
Target:
Research Areas:
Cat. No.: HY-P10587
CAS No.: 2763602-16-8
Synonyms: JNJ-77242113; JNJ-2113; PN-235
Target:
Research Areas:
Cat. No.: HY-P99248
CAS No.: 1612838-76-2
Synonyms: Risankizumab rzaa; BI 655066; ABBV-066
Target:
Research Areas:
Cat. No.: HY-P9931
CAS No.: 1350289-85-8
Synonyms: CNTO 1959
Target:
Research Areas:
Cat. No.: HY-177129
CAS No.: 2978700-29-5
Synonyms: LY4100511; DC-853
Target:
Research Areas:
Simepdekinra (LY4100511; DC-853) is an IL-17A antagonist. Simepdekinra can be used in the research of moderate to severe plaque-type psoriasis .
Cat. No.: HY-153780
CAS No.: 2467732-66-5
Synonyms: DC-806; LY4100504; S-011806
Target:
Research Areas:
Navepdekinra (DC-806) is an orally active, potent interleukin-17A (IL-17A) inhibitor (IC50 = 10.81 nM). Navepdekinra disrupts the IL-17A protein-receptor interaction, suppressing the downstream pro-inflammatory signaling pathway. Navepdekinra inhibits arthritis in a collage-induced arthritis (CIA) rat model. Navepdekinra can be used for psoriasis, psoriatic arthritis, and ankylosing spondylitis .
Cat. No.: HY-P99378
CAS No.: 2158362-38-8
Synonyms: ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab); AbGn-168
Target:
Research Areas:
Cat. No.: HY-P99940
CAS No.: 1791410-27-9
Synonyms: ABT-122
Target:
Research Areas:
Cat. No.: HY-P99012
CAS No.: 1236278-28-6
Target:
Research Areas:
Cat. No.: HY-P99310
CAS No.: 89957-37-9
Synonyms: RG4934
Target:
Research Areas:
Target:
Research Areas:
IRAK4-IN-21 (compound 17) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
Target:
Research Areas:
IRAK4-IN-22 (compound 18) is an orally active, potent and selective IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC50=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .
Synonyms: ME3183; PDE4-IN-14
Research Areas:
Morcamilast (ME3183) is a potent, orally active, selective phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 1.28 nM, 2.33 nM and 1.63 nM against human PDE4A1A, PDE4B1 and PDE4D2, respectively. Morcamilast inhibits the production of TNF-α, IL-12/23p40, IL-23, IL-17A, IL-4, IL-5 and IL-13 in human PBMCs and T cells, and alleviates chronic Oxazolone (HY-126360)-induced dermatitis, Substance P (HY-P0201)-induced pruritus, Imiquimod (HY-B0180)-induced psoriasis-like dermatitis and LPS (HY-D1056)-induced arthritis . Morcamilast is used for the research of psoriasis, atopic dermatitis, psoriatic arthritis and other inflammatory and immune-related diseases .
Cat. No.: HY-158159
Target:
Research Areas:
IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
Cat. No.: HY-P10587A
Synonyms: JNJ-77242113 acetate; JNJ-2113 acetate; PN-235 acetate
Target:
Research Areas:
Cat. No.: HY-169306
Target:
Research Areas:
IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC50s of 0.028 and 0.0047 μM, respectively .
Target:
Research Areas:
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
Cat. No.: HY-141535
CAS No.: 2446803-85-4
Target:
Research Areas:
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
